Breaking News

You are here » Indian-Commodity  :  Equity & Shares  :  Wockhardt gains on receiving final approval from USFDA for Olopatadine HCI

04-Jul2017

Wockhardt gains on receiving final approval from USFDA for Olopatadine HCI

Wockhardt is currently trading at Rs. 609.75, up by 4.70 points or 0.78% from its previous closing of Rs. 605.05 on the BSE.

The scrip opened at Rs. 614.90 and has touched a high and low of Rs. 615.30 and Rs. 609.00 respectively. So far 21,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1129.00 on 21-Jul-2016 and a 52 week low of Rs. 555.00 on 22-Jun-2017.

Last one week high and low of the scrip stood at Rs. 615.30 and Rs. 579.80 respectively. The current market cap of the company is Rs. 6,732.00 crore.

The promoters holding in the company stood at 74.25%, while Institutions and Non-Institutions held 7.26% and 18.49% respectively.

Wockhardt has received final approval from United States Food and Drug Administration (USFDA) for its ANDA for 0.1% ophthalmic solution of Olopatadine HCI. The eye drop Olopatadine HCI 0.1% ophthalmic solution is a generic version of Patanol, marketed at US by Alcon, a subsidiary of Novartis.

The product will be manufactured at USFDA approved contract manufacturing organization based in Montreal, Canada.

Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API's, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.



Related News

View all news

IndusInd Bank surges on reporting 5% rise in Q2 net profit

IndusInd Bank is currently trading at Rs. 1663.60, up by 36.75 points or 2.26% from its previous closing of Rs. 1626.85 on the BSE.The scrip opened at Rs. 1638.00 and has touched a high and low of Rs.......

Lupin rises with arm partnering with ASHA, NPWH

Lupin is currently trading at Rs. 897.00, up by 16.55 points or 1.88% from its previous closing of Rs. 880.45 on the BSE.The scrip opened at Rs. 889.80 and has touched a high and low of Rs. 910.00 and......

Alembic Pharma surges with receiving USFDA's tentative approval for Alogliptin Tablet

Alembic Pharmaceuticals is currently trading at Rs. 602.35, up by 6.50 points or 1.09% from its previous closing of Rs. 595.85 on the BSE.The scrip opened at Rs. 596.65 and has touched a high and low of......

Top News

View all news

Shalimar Paints lays down foundation of Nashik manufacturing plant

Shalimar Paints has laid down the foundation of a manufacturing unit to be rebuilt in Nashik, in the state of Maharashtra. The company set to commence operations by April 2019 with a planned production......

Delta Corp reports 11% rise in Q2 consolidated net profit

Delta Corp has reported results for second quarter ended September 30, 2018.The company has reported over 2-fold jump in its net profit at Rs 63.51 crore for the quarter under review as compared to Rs......

PNB plans to sell non-core assets worth Rs 8,600 crore during FY19

Punjab National Bank (PNB) has recognized various assets, including its housing finance arm, for sale and hopes to realise Rs 8,600 crore from these non-core assets during the current fiscal. Meanwhile,......